Dietary intake variability in the cycle of cytotoxic chemotherapy
Marcin Mardas1,2, Radosław Mądry2, Marta Stelmach-Mardas3,4
1Department of Human Nutrition and Hygiene, Poznan University of Life Science, Poznan, Poland.
Purpose:
This study was conducted to evaluate the dietary intake at different time points of the chemotherapeutic cycle.
Methods:
Fifty-five ovarian cancer patients receiving at least 2 cycles of chemotherapy were deemed eligible for this study, of which 41 participants completed the study. Anthropometrical measurements and Subjective Global Assessment were used to estimate nutritional status. The dietary intake was evaluated by 3-day food records: 3 days prior to, the day of, and the following day after chemotherapy.
Results:
Mean energy intake was the lowest on the day of chemotherapy and the highest 3 days before treatment (mean difference, 413.8 kcal; p < 0.001). Similarly, some vitamins and macro- and micronutrients (K, Ca, vit D, folate, vit C) failed to reach 50 % of the recommended dietary allowances. When dividing patients into BMI categories, the energy intake per kilogram of body weight, in the normal-weight patients, was statistically higher than that in overweight and obese subjects (23.6 vs. 20.9 vs. 12.3 kcal, respectively; p = 0.0015). Similarly, the statistically significant differences were observed by the intake of fats (0.80 vs. 0.69 vs. 0.39 g, p = 0.0283) and carbohydrates (3.52 vs. 3.05 vs. 1.71 g, p = 0.0004).
Conclusions:
Dietary intake varies in the cycle of chemotherapy, with the lowest intake at the day of cytotoxic treatment and the highest before the next chemotherapy. Further studies evaluating dietary intake in patients undergoing chemotherapy should include in the protocol the exact time point of dietary assessment. The intake of energy, fats, and carbohydrates differs significantly across BMI categories.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chronic Kidney Disease III: Interprofessional Care
Dosage Regimen: Individualization
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drug toxicity: Idiosyncratic Reactions


